Insider Trading Alert - OMAM, CBOE And VVUS Traded By Insiders

Yesterday, April 20, 2016, 32 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $178.06 to $3,039,608.80.

Highlighted Stocks Traded by Insiders:

OM Asset Management (OMAM) - FREE Research Report

Bain Peter L, who is Chief Executive Officer at OM Asset Management, sold 29,375 shares at $13.72 on April 20, 2016. Following this transaction, the Chief Executive Officer owned 922,382 shares meaning that the stake was reduced by 3.09% with the 29,375-share transaction.

Belgrad Stephen, who is Evp/Cfo at OM Asset Management, sold 7,175 shares at $13.71 on April 20, 2016. Following this transaction, the Evp/Cfo owned 203,270 shares meaning that the stake was reduced by 3.41% with the 7,175-share transaction.

Riordan Aidan J, who is EVP/Head of Affiliate Mngmt at OM Asset Management, sold 4,306 shares at $13.71 on April 20, 2016. Following this transaction, the EVP/Head of Affiliate Mngmt owned 131,949 shares meaning that the stake was reduced by 3.16% with the 4,306-share transaction.

Gibson Linda T., who is EVP/Head of Global Distributin at OM Asset Management, sold 8,760 shares at $13.72 on April 20, 2016. Following this transaction, the EVP/Head of Global Distributin owned 214,490 shares meaning that the stake was reduced by 3.92% with the 8,760-share transaction.

Hadley Christopher, who is EVP/ Chief Talent Officer at OM Asset Management, sold 708 shares at $13.72 on April 20, 2016. Following this transaction, the EVP/ Chief Talent Officer owned 35,471 shares meaning that the stake was reduced by 1.96% with the 708-share transaction.

The shares most recently traded at $12.77, down $0.95, or 7.4% since the insider transaction. Historical insider transactions for OM Asset Management go as follows:

  • 4-Week # shares bought: 7,500
  • 4-Week # shares sold: 126,475
  • 12-Week # shares bought: 7,500
  • 12-Week # shares sold: 167,220
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 167,220

The average volume for OM Asset Management has been 210,900 shares per day over the past 30 days. OM Asset Management has a market cap of $1.6 billion and is part of the financial sector and financial services industry. Shares are down 15.2% year-to-date as of the close of trading on Wednesday.

OM Asset Management Limited is a privately owned asset management holding company. The firm provides its services to individuals and institutions. It manages separate client focused portfolios through its subsidiaries. The firm also launches equity mutual funds for its clients. The stock currently has a dividend yield of 2.46%. The company has a P/E ratio of 10.1. Currently, there are 3 analysts who rate OM Asset Management a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OMAM - FREE

TheStreet Quant Ratings rates OM Asset Management as a sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full OM Asset Management Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

CBOE Holdings (CBOE) - FREE Research Report

Brodsky William J, who is Director at CBOE Holdings, sold 5,000 shares at $63.87 on April 20, 2016. Following this transaction, the Director owned 227,154 shares meaning that the stake was reduced by 2.15% with the 5,000-share transaction.

The shares most recently traded at $65.00, up $1.13, or 1.74% since the insider transaction. Historical insider transactions for CBOE Holdings go as follows:

  • 4-Week # shares sold: 11,894
  • 12-Week # shares sold: 25,644
  • 24-Week # shares sold: 36,194

The average volume for CBOE Holdings has been 593,700 shares per day over the past 30 days. CBOE Holdings has a market cap of $5.4 billion and is part of the financial sector and financial services industry. Shares are up 0.82% year-to-date as of the close of trading on Wednesday.

CBOE Holdings, Inc., through its subsidiaries, operates as an options exchange and creator of listed options in the United States. The stock currently has a dividend yield of 1.41%. The company has a P/E ratio of 26.6. Currently, there is 1 analyst who rates CBOE Holdings a buy, 2 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CBOE - FREE

TheStreet Quant Ratings rates CBOE Holdings as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels, solid stock price performance and growth in earnings per share. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full CBOE Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Vivus (VVUS) - FREE Research Report

Slebir John L, who is SVP, Business Development & GC at Vivus, sold 2,973 shares at $3.04 on April 20, 2016. Following this transaction, the SVP, Business Development & GC owned 44,555 shares meaning that the stake was reduced by 6.26% with the 2,973-share transaction.

The shares most recently traded at $1.75, down $1.29, or 73.71% since the insider transaction. Historical insider transactions for Vivus go as follows:

  • 4-Week # shares bought: 3,080
  • 4-Week # shares sold: 329
  • 12-Week # shares bought: 3,080
  • 12-Week # shares sold: 329
  • 24-Week # shares bought: 3,080
  • 24-Week # shares sold: 1,882

The average volume for Vivus has been 1.1 million shares per day over the past 30 days. Vivus has a market cap of $170.7 million and is part of the health care sector and drugs industry. Shares are up 74.51% year-to-date as of the close of trading on Wednesday.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. Currently, there is 1 analyst who rates Vivus a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VVUS - FREE

TheStreet Quant Ratings rates Vivus as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Vivus Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

11 Investing Lessons Jim Cramer Has Learned This Year

11 Investing Lessons Jim Cramer Has Learned This Year

Stocks Destined for a Plunge so Don't Let Thursday's Epic Dow Rally Fool You

Stocks Destined for a Plunge so Don't Let Thursday's Epic Dow Rally Fool You

Elon Musk Tells New York Times Tweet Was Attempt at Transparency

Elon Musk Tells New York Times Tweet Was Attempt at Transparency

Jim Cramer on How Companies Benefit From Helping Stakeholders

Jim Cramer on How Companies Benefit From Helping Stakeholders

Jim Cramer Breaks Down the Dramatic Changes Happening at Walmart

Jim Cramer Breaks Down the Dramatic Changes Happening at Walmart